Hallucination in Medical Imaging AI: A Cross-Modality Analytical Framework for Taxonomy, Detection, and Mitigation under Regulatory Constraints
Summary
A cross-modality analytical framework analyzes hallucination in medical imaging AI, synthesizing peer-reviewed studies, benchmark datasets, and FDA regulatory guidance (2023-2026) across five modalities: CT, MRI, PET/SPECT, ultrasound, and digital pathology. The study reveals that no single taxonomic framework is sufficient, requiring integration of three distinct approaches. Counterintuitively, general-purpose foundation models outperform medical-specialized models on hallucination-specific benchmarks, achieving a median hallucination-free rate of 76.6% versus 51.3% (p=0.012). Effective mitigation strategies include physics-informed architectural constraints, Chain-of-Thought prompting (reducing hallucinations by up to 86.4%), and human-in-the-loop safeguards, all mapped to the FDA's Total Product Lifecycle (TPLC) and Predetermined Change Control Plan (PCCP) frameworks, which treat hallucination management as a continuous lifecycle obligation.
Key takeaway
For AI/ML Directors and Research Scientists deploying medical imaging AI, you should prioritize hallucination-specific benchmarks over general accuracy metrics when evaluating models, as general-purpose models surprisingly show lower hallucination rates (76.6% vs. 51.3%). Integrate Chain-of-Thought prompting and robust human-in-the-loop oversight, which reduces false positives by 83.7%, ensuring compliance with FDA's TPLC and PCCP frameworks for continuous lifecycle management.
Key insights
General-purpose AI models surprisingly exhibit lower hallucination rates than specialized medical models on specific benchmarks.
Principles
- Unified taxonomies require integrating multiple frameworks.
- Specialization does not guarantee hallucination robustness.
- Hallucination management is a continuous lifecycle obligation.
Method
A structured narrative design synthesized peer-reviewed studies, benchmark datasets (Med-HallMark, MedHallBench), and FDA guidance (Jan 2025, Dec 2024) across five imaging modalities to analyze taxonomy, etiology, detection, and mitigation.
In practice
- Evaluate models using hallucination-specific benchmarks.
- Implement Chain-of-Thought prompting for up to 86.4% reduction.
- Integrate human-in-the-loop oversight for critical review.
Topics
- Hallucination Detection
- Medical Imaging AI
- FDA Regulatory Compliance
- AI Model Benchmarking
- Vision-Language Models
- AI Mitigation Strategies
Best for: CTO, VP of Engineering/Data, AI Architect, Research Scientist, AI Scientist, Director of AI/ML
Related on AIssential
Editorial summary, takeaway, and curation by AIssential. Original article published by cs.AI updates on arXiv.org.